Suppr超能文献

阿尔茨海默病——一个健康大脑走向器官衰竭的旅程。

Alzheimer's disease - the journey of a healthy brain into organ failure.

机构信息

Departments of Neuroscience and Neurology, Evelyn F. and William L. McKnight Brain Institute, Norman Fixel Institute for Neurological Diseases, Center for Translational Research in Neurodegenerative Disease, University of Florida, Gainesville, Fl, USA.

出版信息

Mol Neurodegener. 2022 Mar 5;17(1):18. doi: 10.1186/s13024-022-00523-1.

Abstract

As the most common dementia, Alzheimer's disease (AD) exacts an immense personal, societal, and economic toll. AD was first described at the neuropathological level in the early 1900s. Today, we have mechanistic insight into select aspects of AD pathogenesis and have the ability to clinically detect and diagnose AD and underlying AD pathologies in living patients. These insights demonstrate that AD is a complex, insidious, degenerative proteinopathy triggered by Aβ aggregate formation. Over time Aβ pathology drives neurofibrillary tangle (NFT) pathology, dysfunction of virtually all cell types in the brain, and ultimately, overt neurodegeneration. Yet, large gaps in our knowledge of AD pathophysiology and huge unmet medical need remain. Though we largely conceptualize AD as a disease of aging, heritable and non-heritable factors impact brain physiology, either continuously or at specific time points during the lifespan, and thereby alter risk for devolvement of AD. Herein, I describe the lifelong journey of a healthy brain from birth to death with AD, while acknowledging the many knowledge gaps that remain regarding our understanding of AD pathogenesis. To ensure the current lexicon surrounding AD changes from inevitable, incurable, and poorly manageable to a lexicon of preventable, curable, and manageable we must address these knowledge gaps, develop therapies that have a bigger impact on clinical symptoms or progression of disease and use these interventions at the appropriate stage of disease.

摘要

作为最常见的痴呆症,阿尔茨海默病(AD)给个人、社会和经济带来了巨大的负担。AD 最早于 20 世纪初在神经病理学层面被描述。如今,我们对 AD 发病机制的某些方面有了机制上的认识,并且有能力在活的患者中临床检测和诊断 AD 以及潜在的 AD 病理。这些认识表明,AD 是一种复杂的、隐袭的、退行性的蛋白病,由 Aβ 聚集物的形成引发。随着时间的推移,Aβ 病理学导致神经原纤维缠结(NFT)病理学、大脑中几乎所有细胞类型的功能障碍,最终导致明显的神经退行性变。然而,我们对 AD 病理生理学的认识仍存在很大差距,而且医疗需求也远未得到满足。尽管我们在很大程度上将 AD 视为一种衰老疾病,但遗传和非遗传因素会影响大脑的生理机能,要么持续影响,要么在生命过程中的特定时间点影响,从而改变发生 AD 的风险。在此,我描述了一个健康的大脑从出生到死亡的一生旅程,同时也承认我们对 AD 发病机制的理解仍然存在许多知识空白。为了确保围绕 AD 的当前词汇从不可避免、不可治愈和难以控制转变为可预防、可治愈和可管理的词汇,我们必须填补这些知识空白,开发出对临床症状或疾病进展有更大影响的治疗方法,并在疾病的适当阶段使用这些干预措施。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8aa4/8898417/e317182e5556/13024_2022_523_Fig1_HTML.jpg

相似文献

引用本文的文献

2
Retinal manifestations and their diagnostic significance in Alzheimer's disease.阿尔茨海默病的视网膜表现及其诊断意义。
J Alzheimers Dis Rep. 2025 Aug 10;9:25424823251361937. doi: 10.1177/25424823251361937. eCollection 2025 Jan-Dec.

本文引用的文献

7
Revisiting FDA Approval of Aducanumab.重新审视阿杜卡努单抗的美国食品药品监督管理局批准情况。
N Engl J Med. 2021 Aug 26;385(9):769-771. doi: 10.1056/NEJMp2110468. Epub 2021 Jul 28.
10
2021 Alzheimer's disease facts and figures.2021 年阿尔茨海默病事实和数据。
Alzheimers Dement. 2021 Mar;17(3):327-406. doi: 10.1002/alz.12328. Epub 2021 Mar 23.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验